Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents

Hormone and Metabolic Research

Volumn 43, Issue 5, 2011, Pages 300-305

  Dokken, B B ^a,b   La Bonte, L R ^a,c   Davis Gorman, G ^a,b   Teachey, M K ^a,b   Seaver, N ^b   McDonagh, P F ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CD11b; GLP 1; ischemia reperfusion injury; myocardial infarction; PMN

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; PLACEBO;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; CELL ACTIVATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; ELECTROCARDIOGRAM; HEART INFARCTION SIZE; HEART RATE; LUNG VENTILATION; LUNG VOLUME; MALE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SPRAGUE DAWLEY RAT; VASODILATATION;

ANIMALS; DISEASE MODELS, ANIMAL; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NEUTROPHIL ACTIVATION; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; RATTUS; RODENTIA;

EID: 79955692561     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1271777     Document Type: Article

References (56)

1. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y, Amer Heart Assoc Stat Comm S. Heart disease and stroke statistics - 2008 update - A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: E25-E146
2. Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med 2008; 263: 517-527 (Pubitemid 351533560)
3. Burke AP, Virmani R. Pathophysiology of acute myocardial infarction. Med Clin North Am 2007; 91: 553-572 (Pubitemid 47058140)
4. Heusch G. Postconditioning: Old wine in a new bottle? J Am Coll Cardiol 2004; 44: 1111-1112
5. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-1135
6. Jordan JE, Zhao ZQ, Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res 1999; 43: 860-878 (Pubitemid 29413185)
7. Ovize M, Baxter GF, Di Lisa F, Ferdinandy Pt, Garcia-Dorado D, Hausenloy DJ, Heusch G, Vinten-Johansen J, Yellon DM, Schulz R. Postconditioning and protection from reperfusion injury: where do we stand? Position Paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2010; 87: 406-423
8. Briones M, Bajaj M. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus. Expert Opin Pharmacother 2006; 7: 1055-1064 (Pubitemid 43949943)
9. Bose AK, Mocanu MM, Carr RD, Yellon DM. Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6 K pathway. Cardiovasc Drugs Ther 2007; 21: 253-256 (Pubitemid 47387464)
10. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005; 54: 146-151 (Pubitemid 40105106)
11. Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1 (9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008; 146: 243-249
12. Timmers L, Henriques JPS, de Kleijn DPV, DeVries JH, Kemperman H, Steendijk P, Verlaan CWJ, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE. Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury. J Am College Cardiol 2009; 53: 501-510
13. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008; 117: 2340-2350 (Pubitemid 351653542)
14. Noyan-Ashraf MH, Momen MA, Ban K, Sadi A-M, Zhou Y-Q, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ. GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice. Diabetes 2009; 58: 975-983
15. Hausenloy D, Baxter G, Bell R, Bøtker H, Davidson S, Downey J, Heusch G, Kitakaze M, Lecour S, Mentzer R, Mocanu M, Ovize M, Schulz R, Shannon R, Walker M, Walkinshaw G, Yellon D. Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations. Basic Res Cardiol 2010; 105: 677-686
16. La Bonte LR, Davis-Gorman G, Stahl GL, McDonagh PF. Complement inhibition reduces injury in the type 2 diabetic heart following ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2008; 294: H1282-H1290 (Pubitemid 351468725)
17. La Bonte LR, Dokken B, Davis-Gorman G, Stahl GL, McDonagh PF. The mannose-binding lectin pathway is a significant contributor to reperfusion injury in the type 2 diabetic heart. Diabetes Vasc Dis Res 2009; 6: 172-180
18. Hokama JY, Ritter LS, Davis-Gorman G, Cimetta AD, Copeland JG, McDonagh PF. Diabetes enhances leukocyte accumulation in the coronary microcirculation early in reperfusion following ischemia. J Diabetes Complicat 2000; 14: 96-107 (Pubitemid 30665760)
19. Legare JF, Oxner A, Heimrath O, Issekutz T. Infiltration of polymorphonuclear cells into the post-ischaemic myocardium is dependent on beta 2 and alpha 4 integrins. Int J Exp Pathol 2007; 88: 291-300 (Pubitemid 47256306)
20. McDonagh PF, Rauzzino MJ. Stimulated leukocyte adhesion in coronary microcirculation is reduced by a calcium antagonist. Am J Physiol Heart Circ Physiol 1993; 265: H476-H483 (Pubitemid 23273581)
21. Hoffmeyer MR, Scalia R, Ross CR, Jones SP, Lefer DJ. PR-39, a potent neutrophil inhibitor, attenuates myocardial ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol 2000; 279: H2824-H2828 (Pubitemid 32005871)
22. Feng Y, Zhao H, Xu X, Buys ES, Raher MJ, Bopassa JC, Thibault H, Scherrer-Crosbie M, Schmidt U, Chao W. Innate immune adaptor MyD88 mediates neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice. Am J Physiol Heart Circ Physiol 2008; 295: H1311-H1318
23. Zerria K, Jerbi E, Hammami S, Maaroufi A, Boubaker S, Xiong JP, Arnaout MA, Fathallah DM. Recombinant integrin CD11b A-domain blocks polymorphonuclear cells recruitment and protects against skeletal muscle inflammatory injury in the rat. Immunology 2006; 119: 431-440 (Pubitemid 44722205)
24. McDonagh PF, Wilson DS, Iwamura H, Smith CW, Williams SK, Copeland JG. CD18 Antibody Treatment Limits Early Myocardial Reperfusion Injury after Initial Leukocyte Deposition. J Surg Res 1996; 64: 139-149 (Pubitemid 26304884)
25. Faxon DP, Gibbons RJ, Chronos NAF, Gurbel PA, Martin JS. The effect of a CD11/CD18 inhibitor (Hu23F2G) on infarct size following direct angioplasty: The HALT MI study. Circulation 1999; 18 (Suppl S): 791-792 (Abstract)
26. Baran KW, Nguyen M, McKendall GR, Lambrew CT, Dykstra G, Palmeri ST, Gibbons RJ, Borzak S, Sobel BE, Gourlay SG, Rundle AC, Gibson CM, Barron HV. Double-blind, randomized trial of an Anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction-Limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation 2001; 104: 2778-2783 (Pubitemid 33126650)
27. Faxon DP, Gibbons RJ, Chronos NAF, Gurbel PA, Sheehan F, Investigators H-M. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: The results of the HALT-MI study. Journal of the American College of Cardiology 2002; 40: 1199-1204
28. John B, Hunter CA. Immunology. Neutrophil soldiers or Trojan Horses? Science 2008; 321: 917-918
29. Duilio C, Ambrosio G, Kuppusamy P, DiPaula A, Becker LC, Zweier JL. Neutrophils are primary source of O2 radicals during reperfusion after prolonged myocardial ischemia. Am J Physiol Heart Circ Physiol 2001; 280: H2649-H2657
30. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004; 61: 481-497 (Pubitemid 38210154)
31. Williams FM. Neutrophils and myocardial reperfusion injury. Pharmacol Therap 1996; 72: 1-12 (Pubitemid 26375472)
32. Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 2010; 298: H1454-H1465
33. Sauve M, Ban K, Momen MA, Zhou Y-Q, Henkelman RM, Husain M, Drucker DJ. Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice. Diabetes 2010; 59: 1063-1073
34. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Myocardial infarct size attenuation by glucagon like peptide-1 (GLP-1) in both in vivo and in vitro rat heart. Diabetologia 2004; 47: A46
35. Bose AK, Mocanu MM, Carr RD, Yellon DM. Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 2005; 19: 9-11 (Pubitemid 40767767)
36. Brubaker PL, Drucker DJ. Minireview: Glucagon-Like Peptides Regulate Cell Proliferation and Apoptosis in the Pancreas, Gut, and Central Nervous System. Endocrinology 2004; 145: 2653-2659 (Pubitemid 38686211)
37. Buteau J. GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival. Diabetes Metab 2008; 34: S73-S77 (Pubitemid 351978286)
38. Greig NH, Mattson MP, Perry T, Chan SL, Giordano T, Sambamurti K, Rogers JT, Ovadia H, Lahiri DK. New therapeutic strategies and drug candidates for neurodegenerative diseases p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists. Ann New York Acad Sci 2004; 1035: 290-315 (Pubitemid 40362340)
39. Kimura R, Okouchi M, Fujioka H, Ichiyanagi A, Ryuge F, Mizuno T, Imaeda K, Okayama N, Kamiya Y, Asai K, Joh T. Glucagon-like peptide- 1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway. Neuroscience 2009; 162: 1212-1219
40. Huisamen B, Genade S, Lochner A. Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the rat heart and their role in protection against ischaemia. Cardiovasc J Africa 2008; 19: 77-83
41. Xie Y, Wang SX, Sha WW, Zhou X, Wang WL, Han LP, Li DQ, Yu DM. Effects and mechanism of glucagon-like peptide-1 on injury of rats cardiomyocytes induced by hypoxia-reoxygenation. Chin Med J 2008; 121: 2134-2138
42. Sulistio M, Carothers C, Mangat M, Lujan M, Oliveros R, Chilton R. GLP- 1 agonist-based therapies: An emerging new class of antidiabetic drug with potential cardioprotective effects. Curr Atheroscler Rep 2009; 11: 93-99
43. Timmers L, Henriques J, de Kleijn D, Devries J, Kemperman H, Steendijk P, Verlaan C, Kerver M, Piek J, Doevendans P, Pasterkamp G, Hoefer I. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009; 53: 501-510
44. Kavianipour M, Ehlers MR, Malmberg K, Ronquist G, Ryden L, Wikstrom G, Gutniak M. Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and nonischemic porcine myocardium. Peptides 2003; 24: 569-578
45. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen Y-T, Shannon RP. Direct Effects of Glucagon-Like Peptide-1 on Myocardial Contractility and Glucose Uptake in Normal and Postischemic Isolated Rat Hearts. J Pharmacol Exp Ther 2006; 317: 1106-1113 (Pubitemid 43764114)
46. Dokken BB, Hilwig WR, Teachey MK, Panchal RA, Huebner K, Allen D, Rogers DC, Kern KB. Glucagon-like peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction. Resuscitation 2010; 81: 755-760
47. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H. Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4. Diabetes 2010; 59: 1030-1037
48. Liu H, Dear A, Knudsen L, Simpson R. A long-acting GLP-1 analogue attenuates induction of PAI-1 and vascular adhesion molecules. J Endocrinol 2009; 201: 59-66
49. Liu HB, Hu YS, Simpson RW, Dear AE. Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasmogen activator inhibitor-1 expression. J Endocrinol 2008; 196: 57-65 (Pubitemid 351234571)
50. Hattori Y, Jojima T, Tomizawa A, Satoh H, Hattori S, Kasai K, Hayashi T. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 2010; 53: 2256-2263
51. Skyschally A, van Caster P, Iliodromitis E, Schulz R, Kremastinos D, Heusch G. Ischemic postconditioning: experimental models and protocol algorithms. Basic Res Cardiol 2009; 104: 469-483
52. Fang J, Wu LM, Chen L. Postconditioning attenuates cardiocyte ultrastructure injury and apoptosis by blocking mitochondrial permeability transition in rats. Acta Cardiologica 2008; 63: 377-387 (Pubitemid 351929846)
53. Jang YG, Xi JK, Wang HH, Mueller RA, Norfleet EA, Xu ZL. Postconditioning prevents Reperfusion injury by activating delta-opioid receptors. Anesthesiology 2008; 108: 243-250 (Pubitemid 351156734)
54. Sato H, Zhao ZO, Jordan JE, Williams MW, Sarvotham SS, Vintenjohansen J. Gradual restoration of reperfusion reduces coronary artery endothelial injury and myocardial infarction. Faseb J 1995; 9: A421
55. Kin H, Zhao Z-Q, Sun H-Y, Wang N-P, Corvera JS, Halkos ME, Kerendi F, Guyton RA, Vinten-Johansen J. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 2004; 62: 74-85 (Pubitemid 38326813)
56. Ban K, Kim K-H, Cho C-K, Sauve M, Diamandis EP, Backx PH, Drucker DJ, Husain M. Glucagon-Like Peptide (GLP)-1 (9-36) Amide-Mediated Cytoprotection Is Blocked by Exendin (9-39) Yet Does Not Require the Known GLP-1 Receptor. Endocrinology 2010; 151: 1520-1531